Neuromuscular Research Grant Competitions from Defeat Duchenne Canada and Myotonic Dystrophy Foundation You Can Apply For Today!
Defeat Duchenne Canada:
Defeat Duchenne Canada is now accepting Letters of Intent (LOI) for its 2025 Research Grant Cycle! As the country’s leading funder of Duchenne muscular dystrophy (DMD) specific research, they are committed to supporting groundbreaking projects that improve care, accelerate treatments, and bring us closer to a cure.
The submission portal opened on March 31, 2025, and researchers worldwide are invited to begin the process by submitting LOI by April 28, 2025. Don’t miss this opportunity to apply for funding for innovative Duchenne research.
Learn more and apply today: https://defeatduchenne.ca/granting-process/
Myotonic Dystrophy Foundation:
The Myotonic Dystrophy Foundation (MDF) supports scientific investigations to enhance the quality of life of people living with myotonic dystrophy and advance research focused on finding treatments and a cure for this disease. As a part of this effort, the MDF offers a number of funding opportunities for DM researchers.
2026 Doctoral and Postdoctoral Research Fellowships
Proposals Due: September 5, 2025
Through this effort, the MDF intends to fund doctoral and postdoctoral research fellowships for projects that focus on basic, translational, and/or clinical research or care in myotonic dystrophy.
Read the fellowship guidelines here!
2026 Early Career Scholar Grant
Proposals Due: September 5, 2025
MDF is accepting applications for Early Career Scholar awards to support the retention of passionate early career researchers in the DM field. These awards are available in both basic/translational science and clinical research streams. Through these awards, MDF seeks to retain early-career scholars who are passionate about DM research.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.